Skip to main content

Table 1 Patients’ demographic characteristics

From: Efficacy and safety of subanesthetic doses of esketamine combined with propofol in painless gastrointestinal endoscopy: a prospective, double-blind, randomized controlled trial

 

Group P

Group PK1

Group PK2

Group PK3

P value

Age (years)

44.94 ± 10.031

42.71 ± 10.148

45.89 ± 9.292

44.38 ± 10.233

0.785

Gender (F)

38 (58.5%)

38 (58.5%)

32 (49.2%)

30 (46.2%)

0.369

Weight (Kg)

61.32 ± 10.053

60.77 ± 9.465

62.97 ± 9.352

60.52 ± 9.816

0.918

Height (cm)

164.20 ± 7.688

163.28 ± 7.966

165.12 ± 7.962

165.65 ± 7.787

0.969

BMI

22.67 ± 2.755

22.74 ± 2.664

23.06 ± 2.770

21.99 ± 2.730

0.961

ASA (I)

43 (66.2%)

39 (60.0%)

42 (64.6%)

42 (64.6%)

0.896

Gastroscope

65(100%)

65(100%)

65(100%)

65(100%)

 

Colonoscopy

65(100%)

65(100%)

65(100%)

65(100%)

 

Comorbidities

Hypertension

19 (29.2%)

21 (32.3%)

19 (29.2%)

16 (24.6%)

0.812

Diabetes

6 (9.2%)

2 (3.1%)

6 (9.2%)

3 (4.6%)

0.377

Asthma

0 (0%)

0 (0%)

1 (1.5%)

0 (0%)

1.000

COPD

0 (0%)

0 (0%)

0 (0%)

0 (0%)

1.000

Tachycardia

7 (10.8%)

2 (3.1%)

8 (12.3%)

4 (6.2%)

0.194

IHD

0 (0%)

1 (1.5%)

0 (0%)

0 (0%)

1.000

Baseline

SpO2 (%)

98.00 ± 0.919

97.82 ± 1.059

98.03 ± 1.000

98.05 ± 0.909

0.504

SBP (mm Hg)

128.32 ± 17.057

126.75 ± 17.317

128.11 ± 17.540

124.85 ± 15.294

0.624

DBP (mm Hg)

78.91 ± 10.728

78.57 ± 11.727

80.25 ± 9.548

75.46 ± 10.499

0.073

HR (bpm)

85.46 ± 16.260

82.86 ± 14.992

84.43 ± 12.993

84.35 ± 14.303

0.793

  1. Data are presented as mean ± SD, or number (%).
  2. BMI body mass index, ASA American Society of Anesthesiologists, COPD chronic obstructive pulmonary disease, IHD ischemic heart disease, DBP diastolic blood pressure, SBP systolic blood pressure, HR heart rate